Apyx Medical Corporation

APYX

US03837C1062

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
1.6 ^USD	0.00%		0.00%	-38.93%

05-09	Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024
05-09	Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical	CI

Bovie Medical Corporation Announces Company Name Change, Effective January 1, 2019

December 12, 2018 at 09:05 pm

Bovie Medical Corporation announced a corporate rebranding and company name change to Apyx Medical Corporation effective January 1, 2019.

Latest news about Apyx Medical Corporation

Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024	05-09
Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical	05-09	CI
Earnings Flash (APYX) APYX MEDICAL CORPORATION Reports Q1 Revenue $10.2M	05-09	MT
Apyx Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024	05-09	CI
Apyx Medical Corporation Announces Board Leadership Transition	05-09	CI
Archon Capital Management Engages with Apyx Medical Corporation	04-05	CI
Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation	04-01	CI
Transcript : Apyx Medical Corporation, Q4 2023 Earnings Call, Mar 21, 2024	03-21
Apyx Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024	03-21	CI
Apyx Medical Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
North American Morning Briefing : Investors -2-	03-21	DJ
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body	01-22	CI
Apyx Medical Reports Q4, Full-Year 2023 Preliminary Revenue	01-08	MT
Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	01-08	CI
Apyx Medical Names Matthew Hill as CFO	11-28	MT
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023	11-28	CI
Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer	11-16	CI
Stephens Adjusts Price Target on Apyx Medical to $5 From $8, Keeps Overweight Rating	11-10	MT
Transcript : Apyx Medical Corporation, Q3 2023 Earnings Call, Nov 09, 2023	11-09
Earnings Flash (APYX) APYX MEDICAL CORPORATION Posts Q3 Revenue $12M, vs. Street Est of $15.4M	11-09	MT
Apyx Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors	11-09	CI
Apyx Medical Corporation Revises Earnings Guidance for the Year 2023	11-09	CI

Chart Apyx Medical Corporation

Duration

Period

More charts

Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.

Sector

Medical Equipment, Supplies & Distribution

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Apyx Medical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.6 USD

Average target price

3.625 USD

Spread / Average Target

+126.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
APYX MEDICAL CORPORATION	-38.93%	55.43M
ABBOTT LABORATORIES	-5.56%	181B
MEDTRONIC PLC	-0.11%	108B
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B
DEXCOM, INC.	+2.64%	50.65B
CENCORA, INC.	+6.58%	43.11B
HOYA CORPORATION	+2.44%	41.3B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B
TERUMO CORPORATION	+15.69%	25.03B
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B

Other Medical Equipment, Supplies & Distribution

Apyx Medical Corporation

Equities

APYX

US03837C1062

Medical Equipment, Supplies & Distribution

Bovie Medical Corporation Announces Company Name Change, Effective January 1, 2019

Latest news about Apyx Medical Corporation

Chart Apyx Medical Corporation

Company Profile

Income Statement Evolution

Ratings for Apyx Medical Corporation

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution